Canada Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The canada nuclear imaging market size is projected to expand from USD 344.62 million in 2025 and USD 363.38 million in 2026 to USD 492.83 million by 2031, registering a CAGR of 6.28% between 2026 to 2031. This report is Segmented by Modality (Positron Emission Tomography, Single Photon Emission CT, Hybrid PET/CT, Hybrid SPECT/CT, Others), Component (Equipment, Software, Accessories & Consumables), Radio-Isotope (Fluorine-18, Technetium-99m, Iodine-123/131, and More), Application (Oncology, and More), End User (Hospitals, and More). Market Forecasts are Provided in Terms of Value (USD).

Canada Nuclear Imaging Market Trends and Insights

Growing Prevalence of Cancer & CVD

Canada registered 247,100 new cancer cases and 88,100 cancer deaths in 2024, while 2.4 million adults live with cardiovascular disease, a burden that is reshaping diagnostic pathways. FDG PET/CT stays central for non-small-cell lung cancer staging, whereas gallium-68 PSMA PET is now displacing conventional imaging for intermediate- and high-risk prostate cancer after Health Canada cleared Pluvicto in 2022. Rubidium-82 cardiac PET attracts cardiology departments because it delivers 75% less radiation than technetium-99m SPECT. Cancer Care Ontario plans six additional PET scanners by 2028, reinforcing capacity in underserved regions.The Canada nuclear imaging market therefore enjoys a 1.8-percentage-point CAGR lift tied directly to disease-burden growth.

Rising Adoption of Hybrid PET/CT & SPECT/CT

The 2022-2023 Canadian Medical Imaging Inventory listed 60 PET/CT and 331 SPECT/CT units compared with 210 standalone SPECT cameras that now average 13.2 years of service. Integrated scanners shorten time-to-diagnosis and reduce interpretive uncertainty because anatomical and functional data are co-registered in one session. New digital platforms such as GE HealthCare’s Omni Legend and Siemens Healthineers’ Biograph Vision Quadra increase photon sensitivity two- to three-fold, which translates into 50% lower dose or 40% faster acquisitions. Provincial health authorities in Nova Scotia and British Columbia funded digital SPECT/CT installations in 2024, signaling growing willingness to back premium technology. Rising hybrid adoption contributes an additional 1.5-percentage-point lift to the Canada nuclear imaging market CAGR.

Radio-Isotope Supply Risks Post-NRU Closure

With domestic molybdenum-99 production absent until BWXT Medical’s ramp-up hits full stride, many hospitals still depend on South African and European reactors for technetium-99m generators. Transport disruptions can delay deliveries of isotopes whose half-life is just six hours, forcing postponement of non-urgent scans. TRIUMF’s direct cyclotron production, though approved, satisfies only a fraction of national demand. British Columbia and Alberta projects will narrow the gap by 2027, but Atlantic provinces and northern territories will remain vulnerable to weather-related shipping delays. The result is a -1.1 percentage-point drag on the Canada nuclear imaging market CAGR.

Other drivers and restraints analyzed in the detailed report include:

• Government Investments in Radiopharmaceutical Capacity
• Digital Detector Innovations Lowering Dose
• High Capex & Opex of Hybrid Scanners

Segment Analysis

Hybrid PET/CT generated 39.35% of modality revenue in 2025, underlining its entrenched role in oncology staging and therapy response. Stand-alone SPECT cameras are declining as hospitals pivot to hybrid SPECT/CT systems that offer both functional and anatomical data without requiring patient relocation. The Canada nuclear imaging market size for hybrid PET/CT modalities is projected to climb at the overall 6.28% CAGR, whereas hybrid PET/MR leads with a 10.24% CAGR due to superior soft-tissue contrast essential for neuro-oncology and inflammatory bowel disease. Equipment makers have responded: GE HealthCare’s 32 cm-axial Omni Legend shortens total-body scan time to 12 minutes, and Siemens Healthineers’ 106 cm-axial Biograph Vision Quadra enables simultaneous multi-organ pharmacokinetics for theranostic dosimetry. Digital cadmium zinc telluride detectors in next-generation SPECT/CT deliver twice the photon sensitivity of legacy photomultiplier tubes, permitting 50% dose cuts that help labs meet dose-optimization mandates. Hospitals in Halifax and Nanaimo adopted such systems in 2024, evidencing readiness to pay premium prices when dose savings and higher throughput combine. As old SPECT fleets age out - the average system is 13.2 years - the Canada nuclear imaging market share held by hybrid scanners will keep widening.

Equipment captured 63.63% of component revenue in 2025 because several provinces budgeted for hybrid-scanner replacements, but software subscriptions are rising at 9.57% annually as AI-driven image-reconstruction and lesion-quantification tools become standard. The Canada nuclear imaging market size tied to software is therefore growing faster than hardware even though suppliers often bundle first-year licenses with scanner deals. AI-assisted quantification from Siemens’ AI-Rad Companion or GE HealthCare’s Edison platform cuts radiologist reading time 30%-40%, a critical benefit when staffing is tight. Vendors now price upgrades on a per-study or annual-license basis, creating resilient recurring revenue. Consumables such as radiopharmaceutical doses and quality-control phantoms ride on procedure volumes, which expand at the overall 6.28% CAGR. BWXT Medical’s domestic yttrium-90 and indium-111 production will further anchor recurring consumable revenue as isotope self-sufficiency improves.

Complete Report Scope:

• By Modality
  • Positron Emission Tomography (PET)
  • Single Photon Emission CT (SPECT)
  • Hybrid PET/CT
  • Hybrid SPECT/CT
  • Others (e.g., PET/MR)
• By Component
  • Equipment
  • Software
  • Accessories & Consumables
• By Radio-isotope
  • Fluorine-18
  • Technetium-99m
  • Iodine-123/131
  • Gallium-68
  • Rubidium-82
  • Others
• By Application
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes
  • Others

List of Companies Covered in this Report:

• Advanced Cyclotron Systems Inc.
• Bracco Imaging S.p.A.
• BWXT Medical Ltd.
• Canon
• CPDC
• Curium Pharma
• Cyclomedica Canada Inc.
• Eckert & Ziegler Radiopharma
• GE Healthcare
• Isologic Innovative Radiopharmaceuticals
• IsoTherapeutics Group LLC
• Jubilant Radiopharma (DraxImage)
• Koninklijke Philips
• Lantheus
• Nordion
• Siemens Healthineers
• Spectrum Dynamics Medical
• TRIUMF Innovations
• United Imaging Healthcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support